CCM
KPTI icon

Catalio Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Catalio Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.19M Buy
940,855
+43,146
+5% +$374K 1.73% 22
2026
Q1 		$5M Buy
897,709
+754,725
+528% +$5.75M 1.04% 29
2025
Q4 		$1.05M Hold
142,984
– – 0.19% 41
2025
Q3 		$935K Sell
142,984
-3,029
-2% -$16.3K 0.17% 36
2025
Q2 		$629K Sell
146,013
-9,609
-6% -$47.1K 0.13% 35
2025
Q1 		$582K Sell
155,622
-3
-0% -$26 0.14% 33
2024
Q4 		$1.58M Buy
+155,625
New +$1.88M 0.35% 28

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM

Catalio Capital Management's KPTI Position: Q2 2026 in Review

Catalio Capital Management increased its Karyopharm Therapeutics (KPTI) stake by 4.8% in Q2 2026, buying an estimated $374K and bringing the position to 940,855 shares worth $9.19M. The position accounts for 1.73% of the portfolio, ranked #22.

Catalio Capital Management first reported a position in KPTI in Q4 2024 and has held it in 7 quarters since. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Catalio Capital Management held 940,855 shares of Karyopharm Therapeutics worth $9.19M as of Q2 2026.
  • Catalio Capital Management bought 43,146 Karyopharm Therapeutics shares in Q2 2026, an estimated $374K.
  • Karyopharm Therapeutics made up 1.73% of Catalio Capital Management's portfolio in Q2 2026, its #22 holding.
  • Catalio Capital Management first reported a position in Karyopharm Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Catalio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.